JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258323

Human B4GALT1 knockout HeLa cell lysate

Be the first to review this product! 리뷰 제출

|

(0 출판물)

B4GALT1 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.
2 이미지
Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (AB258323)
  • Sanger seq

Unknown

Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (AB258323)

Allele-1 : 5 bp deletion in exon 1

Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (AB258323)
  • Sanger seq

Unknown

Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (AB258323)

Allele-2 : 1 bp insertion in exon 1

주요 정보

세포 유형

HeLa

Species or organism

Human

조직

Cervix

Knockout 검증

Sanger Sequencing

Mutation 정보

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.

질병

Adenocarcinoma

제품 세부 정보

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

제품 구성

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258323-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human B4GALT1 knockout HeLa cell lysate", "number":"AB258323-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258323-CMP02", "productcode":"" } ] } } }

특성 및 보관 정보

유전자명
B4GALT1
유전자 편집 종류
Knockout
유전자 편집 방식
CRISPR technology
Knockout 검증
Sanger Sequencing
배송 시 보관 조건
Ambient - Can Ship with Ice
적절한 단기 보관 조건
-20°C
적절한 장기 보관 조건
-20°C

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

B4GALT1 also known as beta-14-galactosyltransferase 1 is an enzyme that facilitates the transfer of galactose residues from UDP-galactose to acceptor sugars forming β1-4 galactosidic linkages. This enzyme has an approximate mass of 60 kDa. It is primarily expressed in the Golgi apparatus of many cell types including epithelial cells and fibroblasts. B4GALT1 represents one of seven beta-14-galactosyltransferase enzymes each with varying specificity and function depending on the tissue type.
Biological function summary

B4GALT1 plays an important role in the modification of glycoproteins and glycolipids. It acts as part of a larger complex responsible for the formation and maintenance of glycan structures on cellular proteins which are important for cell-cell communication and protein stability. This modification process is essential for normal cellular functions because it impacts protein folding secretion and cell surface expression. B4GALT1 achieves this by participating in the synthesis of N-linked and O-linked glycans which directly influences various physiological processes.

Pathways

B4GALT1 functions in the glycosylation pathway where it modifies oligosaccharide chains during protein post-translational modification. This pathway is essential for the synthesis of glycoproteins which play a role in cell adhesion and signaling. B4GALT1 also contributes to the protein N-glycosylation metabolic pathway and interacts with proteins like ST3GAL1 which modify glycan structures further. These pathways are indispensable for proper cellular communication and function.

Defects or dysregulation of B4GALT1 can lead to conditions such as congenital disorders of glycosylation. Mutations in this enzyme have been linked to neurological and developmental abnormalities due to impaired glycan synthesis. B4GALT1 has also shown relevance in cancer influencing tumor progression and metastasis. It interacts with MUC1 a protein that when aberrantly glycosylated can promote cancer cell invasiveness and impede immune response therefore affecting cancer prognosis.

품질 관리

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

제품 프로토콜

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com